Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"ZYUS Life Sciences"},{"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Life Sciences Partners with Portugal\u2019s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"ZYUS Life Sciences"}]

ZYUS Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ZYUS Life Sciences Partners with Portugal’s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids

Details:

Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.

Lead Product(s): Trichomylin

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Aureuspharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 27, 2021

ASK
US

Upload
your Pipeline Activity

ZYUS Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials

Details:

ZYUS Life Sciences will be launching a first-in-human (FIH) clinical trial on the safety, tolerability and efficacy of its lead drug product candidate, Trichomylin®, through its wholly owned subsidiary, ZYUS Life Sciences Australia Pty. Ltd.

Lead Product(s): Trichomylin

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 19, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY